Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,209,695
  • Shares Outstanding, K 47,551
  • Annual Sales, $ 28,630 K
  • Annual Income, $ -66,150 K
  • 60-Month Beta 1.56
  • Price/Sales 74.84
  • Price/Cash Flow N/A
  • Price/Book 6.50
Trade PTGX with:

Options Overview

Details
  • Implied Volatility 72.39%
  • Historical Volatility 35.55%
  • IV Percentile 4%
  • IV Rank 11.90%
  • IV High 113.43% on 09/18/20
  • IV Low 66.85% on 08/23/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.67
  • Number of Estimates 6
  • High Estimate -0.57
  • Low Estimate -0.73
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -219.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.76 +5.42%
on 09/13/21
50.54 -8.73%
on 09/07/21
-1.72 (-3.59%)
since 08/16/21
3-Month
41.28 +11.76%
on 06/17/21
50.54 -8.73%
on 09/07/21
+4.42 (+10.60%)
since 06/16/21
52-Week
17.44 +164.51%
on 10/30/20
50.54 -8.73%
on 09/07/21
+24.98 (+118.11%)
since 09/16/20

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Awards

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on , it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer...

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the appointment of , M.D., to the role of Executive Vice President and Therapeutic Head, Gastroenterology....

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand Pharma by reducing future...

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -11.29% and -59.55%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics: Q2 Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Wednesday reported a loss of $30.8 million in its second quarter.

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financial results for the second quarter ended , and an overview of recent company progress....

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Restated Agreement") with Janssen...

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics Reports Granting of Inducement Award

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on , it issued an inducement award to , the Company's recently hired Vice President, Quality Assurance, in accordance with...

PTGX : 46.13 (-0.73%)
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,503,311...

JPM : 158.09 (-0.04%)
PTGX : 46.13 (-0.73%)
Interesting PTGX Put And Call Options For August 20th

Investors in Protagonist Therapeutics Inc saw new options become available this week, for the August 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTGX...

PTGX : 46.13 (-0.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 47.40
2nd Resistance Point 46.97
1st Resistance Point 46.55
Last Price 46.13
1st Support Level 45.70
2nd Support Level 45.27
3rd Support Level 44.85

See More

52-Week High 50.54
Last Price 46.13
Fibonacci 61.8% 37.90
Fibonacci 50% 33.99
Fibonacci 38.2% 30.08
52-Week Low 17.44

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar